ArrePath
Prior to joining the TB Alliance in early 2021 to focus on development of new therapies for tuberculosis, Todd was Executive Director for Merck’s Infectious Diseases and Vaccines Basic Research group. He has over 25 yrs of experience working on the discovery and development of novel therapies for infectious diseases at Novartis, Schering-Plough and Merck. Todd and his research teams have supported the discovery and development of a variety therapies for prevention and treatment of infectious diseases, including new classes of antibiotics, antifungals for invasive infections, HIV and HCV antivirals, new classes of agents for treating and preventing recurrent C. difficile infections, in addition to vaccines to prevent prevalent respiratory and invasive infections. Todd’s passion has been on the prevention and treatment of emerging pathogens including multi-drug resistant bacteria and other emerging pathogens. Todd earned his Ph. D. in Biochemistry at Michigan State University/DOE Plant Research Laboratory.
This person is not in the org chart
This person is not in any offices
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.